• Accelerating global revenue growth, delivering US$23.8 million, +34% vs prior corresponding period
• US revenues +35% vs prior corresponding period, driven by growth in active physicians and physician utilisation
• FY26 revenue guidance increased to US$87 million, representing 24% year-over-year growth

Saluda Medical, Inc. (ASX:SLD) has reported its Q3 FY26 results, delivering strong global revenue growth of 34% year-over-year to US$23.8 million. This performance was driven by continued commercial momentum in the US, with revenues up 35% versus the prior corresponding period, supported by 32% growth in active physicians and 18% growth in active physician utilisation. International revenues also grew 31% year-over-year, driven by continued growth in customer demand across Europe and Australia. The company's US implanted patient base increased by 55% versus the prior corresponding period, supported by growth in active implanting physicians, trained US sales representatives, and share gains in high volume ambulatory surgery centers. Saluda's sales force expansion remains on track, with the company expecting an average of 89 fully trained sales representatives for FY26 and more than 154 total sales representatives by the end of FY26. Reflecting this strong operational performance, Saluda has increased its FY26 revenue guidance to US$87 million, representing 24% year-over-year growth. The company continues to progress the international rollout of its EVA automated programming platform, with a limited commercial launch in Europe and Australia during the quarter, and a full commercial launch in Europe underway. Saluda also continued to expand its physician education and training efforts, engaging with more than 800 healthcare professionals during the quarter.

Saluda has increased its FY26 revenue guidance to US$87 million, representing forecasted growth of approximately 24% vs FY25.